Research Trials

From Today’s Study, Tomorrow’s Solution.

At Urology of Virginia, research studies form a vital component of our mission. These studies, referred to as clinical trials, are designed by physicians and researchers to investigate new medical therapies. Well-designed clinical trials offer the newest, most promising drugs and treatments for urological conditions to our community.

Our staff’s experienced investigators and certified clinical research coordinators closely monitor participating patients during the course of a study period. All clinical trials are conducted according to the principles of Good Clinical Practice (GCPs) as mandated by the FDA.

Why sign up to participate in a clinical research trial?

  • Participants have access to advanced medications or devices before they become available to the public.
  • Clinical study procedures may be provided to you at no cost.
  • Participants often express enthusiasm for contributing to medical science.
  • Today’s clinical research can positively impact future generations.

Enrolling Clinical Studies at Urology of Virginia

Enrolling Bladder Cancer Studies at Urology of Virginia

Genomic Health: “Urine collection genomic marker study”

This is a urine and cancerous tissue sample collection study for men and women with diagnosed non-muscle invasive bladder cancer. These tissues will be used to validate an assay for predicting recurrence of bladder cancer.


Heat Biologics:“Vaccine Study for Bladder Cancer”

This is a treatment study for bladder cancer patients who require treatment with bacillus Calmette-Guérin (BCG). Patients who participate in this study could receive one of two doses of HS-410, an investigational vaccine, in addition to the BCG.

For more detailed information about this clinical trial please click here.


Enrolling Prostate Cancer Studies at Urology of Virginia

Biopsy

Exact Imaging Ultrasound: “Comparing high resolution and standard resolution ultrasounds”

Men who have an indication for a prostate biopsy are eligible to participate in this study. Those previously diagnosed with prostate cancer are not eligible for this study. Study physicians will either use the routine ultrasound or the study’s high-resolution ultrasound when conducting the biopsy.

For more detailed information about this clinical trial please click here.


Expected Management/Active Surveillance

Canary PASS: a multicenter, prospective active surveillance study with selective intervention in patients with previously untreated, clinically localized prostate cancer at diagnosis. The objective is to discover and confirm biomarkers that predict aggressive disease.


Cancer That Has NOT Spread Beyond the Prostate

Medivation EMBARK: “Recurrent disease after prostatectomy or radiation therapy”

Study is designed for men who were initially treated by prostatectomy or radiotherapy, or both, and who are now experiencing a recurrence in disease. Qualified subjects receive one of three treatments.

For more detailed information about this clinical trial please click here.


Medivation PROSPER:“PSA rising while on hormone therapy”

This study is intended for patients who no longer respond to hormone therapy and whose cancer has not spread to the bone or soft tissue. Qualified subjects will either receive study drug enzalutamide or placebo.

For more detailed information about this clinical trial please click here.


Aragon ARN-509 SPARTAN:“PSA rising while on hormone therapy”

This study is intended for patients who no longer respond to hormone therapy and whose cancer has not spread to the bone or soft tissue. Qualified subjects will either receive study drug ARN-509 or placebo.

For more detailed information about this clinical trial please click here.


Ferring PRONOUNCE: “Hormone therapy for men with heart disease”

Purpose of this trial is to test if a marketed drug for advanced prostate cancer (FIRMAGON) can reduce the risk of cardiovascular complications as compared to another marketed drug for advanced prostate cancer (LUPRON DEPOT) in patients with prostate cancer and cardiovascular disease. Qualified patients for this study will receive either Firmagon® or Lupron

For more detailed information about this clinical trial please click here.


Cancer That Has Spread to Other Areas

Janssen TITAN: “Additional therapy for cancer responding to hormone treatment

A study for men with metastatic prostate cancer who respond to hormone therapy. All subjects will receive standard of care hormone therapy with or without the addition of ARN-509.

For more detailed information about this clinical trial please click here.


Janssen ACIS: “Combination therapy for cancer that is not responding to hormone therapy”

All enrolled subjects will receive abiraterone acetate. Fifty percent of subjects will also receive investigational ARN-509. Both medications are pills taken daily.

For more detailed information about this clinical trial please click here.


Tokai ARMOR3-SV7: “Comparing different drug treatments for men identified with a genetic variant”

All candidates will be screened by a blood test to determine if they are positive for the AR-V7. If positive, subject will enter the study and receive either enzalutamide or galeterone, both oral drugs for men with castrate resistant prostate cancer.

For more detailed information about this clinical trial please click here.


Ferring PRONOUNCE: “Hormone therapy for men with heart disease”

Purpose of this trial is to test if a marketed drug for advanced prostate cancer (FIRMAGON) can reduce the risk of cardiovascular complications as compared to another marketed drug for advanced prostate cancer (LUPRON DEPOT) in patients with prostate cancer and cardiovascular disease. Qualified patients for this study will receive either Firmagon® or Lupron®.

For more detailed information about this clinical trial please click here.


Bayer REASSURE: “Registry study of patients receiving Xofigo®”

Patients with prostate cancer that has spread to the bone may be enrolled in this registry study when they receive Xofigo® treatments.

For more detailed information about this clinical trial please click here.


Bayer ERA223: “Comparison of treatments used for disease that has spread to the bones”

This study is an option for men with disease that has spread to the bone, but who are not suffering from pain related to their cancer. All patients receive abiraterone and 50% may also receive radium 223 in addition to the abiraterone.

For more detailed information about this clinical trial please click here.


Churchill Pharma: “Evaluating testosterone levels when using either Zytiga® or Solumatrix™ Abiraterone”

Qualified patients receive either Zytiga® or SoluMatrix™ Abiraterone Acetate. Serum testosterone levels are evaluated at day 10.

For more detailed information about this clinical trial please click here.



Enrolling Kidney Cancer Studies at Urology of Virginia


No Enrolling Studies at This Time


Enrolling Urologic Studies at Urology of Virginia

Stone Disease

Allena ALLN-177 2 Studies: “Evaluating a new drug for a specific type of kidney stone”

This study is for men and women who have a history of calcium oxalate kidney stones.

For more detailed information about this clinical trial please click here.


Incontinence

Ipsen CONTENT1 “Dysport® for urinary incontinence due to multiple sclerosis (MS) or spinal cord injury (SCI)”

This study is designed for men and women who have urinary incontinence and require clean intermittent catherization (CIC) to manage their bladder function. All patients must have neurogenic bladder as a result of either multiple sclerosis, or a spinal cord injury (T1 or below). Qualified patients will receive Dysport® (abobotulinumtoxin A) injections to the bladder

For more detailed information about this clinical trial please click here.


Astellas PERSPECTIVE “Registry study for overactive bladder therapy”

This registry study is open to both males and females diagnosed with OAB (overactive bladder). Included patients will be starting a new treatment regimen with either mirabegron (Myrbetriq®) or other antimuscarinic medication.

For more detailed information about this clinical trial please click here.


Pelvic Organ Prolapse

No Enrolling Studies at This Time


Hypogonadism

No Enrolling Studies at This Time


Interstitial Cystitis/Bladder Pain Syndrome

This study is designed for males and females who have moderate to severe symptoms of bladder pain for at least nine months. Qualified subjects may receive one dose of study medication (3 chances) or placebo (1 chance). This is a short study and only requires 3 visits to the office.


BPH (Enlarged Prostate)

Neotract MedLift “Treatment for men with BPH and an enlarged median lobe”

This study will use the UroLift® system to treat men who have been determined to have an enlarged median prostatic lobe.

For more detailed information about this clinical trial please click here.


Nocturia

No Enrolling Studies at This Time